Article

Prebiotic oligosaccharides reduce stool viscosity and accelerate gastrointestinal transport in preterm infants

Department of Paediatrics, Deaconry Hospital, Schwaebisch Hall, Germany.
Acta Paediatrica (Impact Factor: 1.84). 08/2006; 95(7):843-8. DOI: 10.1080/08035250500486652
Source: PubMed

ABSTRACT To investigate whether a mixture of prebiotic non-digestible oligosaccharides (GosFos; referring to galacto- and fructo-oligosaccharides) would improve feeding tolerance in preterm infants on full enteral formula feeding. We hypothesized that GosFos would: (1) reduce stool viscosity and (2) accelerate gastrointestinal transport.
In a placebo-controlled double-blind trial 20 preterm infants on full enteral nutrition (gestational age 27 (24-31) weeks, postnatal age 42 (11-84) days, and weight at study entry 1570 (1080-2300) g were randomly allocated to have their feedings supplemented with either GosFos (1 g/100 mL) or placebo for 14 days. Stool viscosity was measured by high-pressure capillary rheometry. Gastrointestinal transport time was assessed as the time from feeding carmine red to its appearance in the diaper. The hypotheses were tested as a priori ordered hypotheses. Data are shown as median (range).
Birth weight, gestational age, postnatal age, and weight at study entry did not differ between groups. GosFos significantly reduced both stool viscosity, as measured by extrusion force (32 (2-67) versus 158 (24-314) N), and gastrointestinal transit time (12 (4-33) versus 26 (5-52) h). No adverse effects were observed.
Formula supplementation with GosFos reduced stool viscosity and accelerated gastrointestinal transport. Further trials are required to investigate whether GosFos facilitates enteral feeding advancement and early enteral nutrition thereby eventually reducing the incidence of catheter-related nosocomial infections and improving long-term outcome.

Download full-text

Full-text

Available from: Frank Pohlandt, Jul 29, 2015
0 Followers
 · 
214 Views
  • Source
    • "Full Term Numico Mihatsch 2006 [66] Pre-Term Milupa GmbH Magne 2008 [67] Full Term Numico Mihatsch 2010 [68] Pre-Term Nestle Mah 2007 [69] "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is little or no information available on the impact of funding by the food industry on trial outcomes and methodological quality of synbiotics, probiotics and prebiotics research in infants. The objective of this study was to compare the methodological quality, outcomes of food industry sponsored trials versus non industry sponsored trials, with regards to supplementation of synbiotics, probiotics and prebiotics in infant formula. A comprehensive search was conducted to identify published and unpublished randomized clinical trials (RCTs). Cochrane methodology was used to assess the risk of bias of included RCTs in the following domains: 1) sequence generation; 2) allocation concealment; 3) blinding; 4) incomplete outcome data; 5) selective outcome reporting; and 6) other bias. Clinical outcomes and authors' conclusions were reported in frequencies and percentages. The association between source of funding, risk of bias, clinical outcomes and conclusions were assessed using Pearson's Chi-square test and the Fisher's exact test. A p-value < 0.05 was statistically significant. Sixty seven completed and 3 on-going RCTs were included. Forty (59.7%) were funded by food industry, 11 (16.4%) by non-industry entities and 16 (23.9%) did not specify source of funding. Several risk of bias domains, especially sequence generation, allocation concealment and blinding, were not adequately reported. There was no significant association between the source of funding and sequence generation, allocation concealment, blinding and selective reporting, majority of reported clinical outcomes or authors' conclusions. On the other hand, source of funding was significantly associated with the domains of incomplete outcome data, free of other bias domains as well as reported antibiotic use and conclusions on weight gain. In RCTs on infants fed infant formula containing probiotics, prebiotics or synbiotics, the source of funding did not influence the majority of outcomes in favour of the sponsors' products. More non-industry funded research is needed to further assess the impact of funding on methodological quality, reported clinical outcomes and authors' conclusions.
    BMC Medical Research Methodology 11/2013; 13(1):137. DOI:10.1186/1471-2288-13-137 · 2.17 Impact Factor
  • Source
    • "Supplementation of the same formula with a mixture of scGOS and lcFOS resulted in a reduction in stool consistency and an increase in stool frequency. More recently, Mihatsch et al. (2006) demonstrated a clinically relevant reduction in the gastrointestinal transit time in preterm infants fed a formula supplemented with these prebiotics. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Twenty one male Wistar albino rats each weighing approximately 280 g were used in this study. Animals were divided into three groups. The first group (n = 7) consisted of sham controls, in the second (n = 7), rats were administrated 0.1 g/1 ml/galactooligosaccharide by by oral gavage for 4 weeks. In the third group (n = 7), rats were administrated 10 9 CFU/1ml/day Bifidobacterium lactis by oral gavage for 4 weeks. After 4 weeks, rats were sacrified; ileum and proximal colon segments were removed. The spontaneous contractions of ileum and proximal colon were evaluated by using organ bath. It has been detected that both prebiotics and probiotics increased intestinal motility. While probiotics have effects on both ileum and proximal colon, prebiotics seem to be effective in colon. All data are expressed as mean ± SEM (standard error of mean). Statistical comparisons between groups were performed using general linear models of analysis of variance (ANOVA) followed by the Turkey test.
    African journal of microbiology research 12/2011; 5(32). DOI:10.5897/AJMR11.801 · 0.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate the use of prebiotics (oligosac- charides) in child health, their applications and possible mechanisms of action. Data source: The articles for this review were electroni- cally selected from the Biblioteca Regional de Medicina (Bireme) virtual library database, which includes Lilacs, Medline and SciELO databases. Search included articles on the subject from 1998 to 2008 comprising children up to 12 years old. Data synthesis: The prebiotic oligosaccharides in food products provided beneficial effects that included increase in total number of bifidobacteria, reduction in the number of pathogenic intestinal microorganisms; improvement of excrement consistency and in the frequency of evacuations These effects suggest their recommendation for constipated children. Beneficial results were verified in several studies concerning the reduction of allergies development, res- piratory infections, fever, irritability, flatulence, diarrhea, regurgitation, vomits, colic, cry and use of antibiotics, with improvement of fermentation characteristics of fatty acids and fecal pH. Nevertheless, the number of studies found indicates the need for further investigation. Studies on cal- cium absorption were contradictory. Concerning tolerance, it is impossible to verify the safety of these products due to the use of diverse quantities of supplement for children from different age ranges and clinical characteristics Conclusions: Although prebiotics seem promising and provide beneficial effects in certain situations, they deserve further investigation to evaluate their actual ef-
Show more